A low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients

BMC Nephrology

Elvira Fernández¹  José M Valdivielso²  Felipe Sarro¹  Montserrat Martinez-Alonso³  Adriana Dusso²  Lourdes Craver¹ 

[1]Nephrology Service and Unit for the Detection and Treatment of Atherothrombotic diseases (UDETMA), Hospital Universitari Arnau de Vilanova, Av Rovira Roure, 25198 Lleida, Spain

[2]Experimental Nephrology Laboratory, IRBLLEIDA, Av. Rovira Roure 80, 25198 Lleida, Spain

[3]Statistics Department, IRBLLEIDA, Av. Rovira Roure 80, Lleida, Spain

关键词: Soluble klotho;    Atherosclerosis;    Fractional excretion of phosphate;    FGF23;    Vascular calcification;   

Others  :  1082818
DOI  :  10.1186/1471-2369-14-221

 received in 2013-06-04, accepted in 2013-10-09,  发布年份 2013

【 摘 要 】

Background

Vascular calcification (VC) contributes to high mortality rates in chronic kidney disease (CKD). High serum phosphate and FGF23 levels and impaired phosphaturic response to FGF23 may affect VC. Therefore, their relative contribution to abdominal aortic calcification (AAC) was examined in patients CKD stages 3–4.

Methods

Potential risk factors for AAC, measured by the Kauppila Index (KI), were studied in 178 patients.

Results

In multivariate linear analysis, AAC associated positively with age, male gender, CKD-stage, presence of carotid plaques (CP) and also with FGF23, but negatively with fractional excretion of phosphate (FEP). Intriguingly, FEP increased with similar slopes with elevations in PTH, with reductions in GFR, and also with elevations in FGF23 but the latter only in patients with none (KI = 0) or mild (KI = 1-5) AAC. Lack of a FEP-FGF23 correlation in patients with severe AAC (KI > 5) suggested a role for an impaired phosphaturic response to FGF23 but not to PTH in AAC. Logistic and zero-inflated analysis confirmed the independent association of age, CKD stage, male gender and CP with AAC, and also identified a threshold FEP/FGF23 ratio of 1/3.9, below which the chances for a patient of presenting severe AAC increased by 3-fold. Accordingly, KI remained unchanged as FEP/FGF23 ratios decreased from 1/1 to 1/3.9 but markedly increased in parallel with further reductions in FEP/FGF23 < 1/3.9.

Conclusions

In CKD 3–4, an impaired phosphaturic response to FGF23 with FEP/FGF23 < 1/3.9 associates with severe AAC independently of age, gender or CP.

【 授权许可】

   
2013 Craver et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005, 68:1815-1824.
• [2]Merjanian R, Budoff M, Adler S, Berman N, Mehrotra R: Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int 2003, 64:263-271.
• [3]Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE: Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004, 44:1024-1030.
• [4]Porter CJ, Stavroulopoulos A, Roe SD, Pointon K, Cassidy MJD: Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stages 3 and 4, with and without diabetes. Nephrol Dial Transplant 2007, 22:3208-3213.
• [5]London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003, 18:1731-1740.
• [6]Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002, 39:695-701.
• [7]Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001, 38:938-942.
• [8]Moe SM, Drueke T: Improving global outcomes in mineral and bone disorders. Clin J Am Soc Nephrol 2008, 3(Suppl 3):S127-S130.
• [9]Craver L, Marco MP, Martinez I, Rue M, Borras M, Martin ML, Sarro F, Valdivielso JM, Fernandez E: Mineral metabolism parameters throughout chronic kidney disease stages 1–5–achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007, 22:1171-1176.
• [10]Inaba M, Okuno S, Imanishi Y, Yamada S, Shioi A, Yamakawa T, Ishimura E, Nishizawa Y: Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006, 17:1506-1513.
• [11]Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009, 24:2792-2796.
• [12]Nasrallah MM, El Shehaby AR, Salem MM, Osman NA, El Sheikh E, El Din UAAS: Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010, 25:2679-2685.
• [13]Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA: FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012, 23:2017-2025.
• [14]Scialla JJ, Ling LW, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, et al.: Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013, 83:1159-1168.
• [15]Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, et al.: FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012, 122:2543-2553.
• [16]Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005, 16:2205-2215.
• [17]Shimada T, Yoneya T, Hino R, Takeuchi Y, Fukumoto S, Yamashita T: Transgenic mice expressing fibroblast growth factor 23 (FGF23) demonstrate hypophosphatemia with low serum 1,25-dihydroxyvitamin D [1,25(OH)2D] and rickets/osteomalacia. J Bone Miner Res 2001, 16:S151.
• [18]Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, Hsiao LL: Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012, 125:2243-2255.
• [19]Dominguez JR, Shlipak MG, Whooley MA, Ix JH: Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes. J Am Soc Nephrol 2013, 24:647-654.
• [20]Amann K: Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 2008, 3:1599-1605.
• [21]Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, et al.: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
• [22]Mirza MA, Hansen T, Johansson L, Ahlstrom H, Larsson A, Lind L, Larsson TE: Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 2009, 24:3125-3131.
• [23]Coll B, Betriu A, Martinez-Alonso M, Amoedo ML, Arcidiacono MV, Borras M, Valdivielso JM, Fernandez E: Large artery calcification on dialysis patients is located in the intima and related to atherosclerosis. Clin J Am Soc Nephrol 2011, 6:303-310.
• [24]Eknoyan G, Levin A, Levin NW: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42:S1-201.
• [25]Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999, 130:461-470.
• [26]Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal-failure. Kidney Int 1985, 27:58-65.
• [27]Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PWF: New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: A 25-year follow-up study. Atherosclerosis 1997, 132:245-250.
• [28]Coll B, Betriu A, Martinez-Alonso M, Borras M, Craver L, Amoedo ML, Marco MP, Sarro F, Junyent M, Valdivielso JM, et al.: Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: usefulness of non-invasive tests in cardiovascular assessment. Nephrol Dial Transplant 2010, 25:3017-3025.
• [29]Kuro O: Klotho in health and disease. Curr Opin Nephrol Hypertens 2012, 21:362-368.
• [30]Bellasi A, Ferramosca E, Muntner P, Ratti C, Wildman RP, Block GA, Raggi P: Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients. Kidney Int 2006, 70:1623-1628.
• [31]Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R III: Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 1979, 66:790-796.
• [32]London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, De Vernejoul MC: Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008, 19:1827-1835.
• [33]Sullivan TR Jr, Karas RH, Aronovitz M, Faller GT, Ziar JP, Smith JJ, O’Donnell TF Jr, Mendelsohn ME: Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 1995, 96:2482-2488.
• [34]Verbeke F, Van Biesen W, Honkanen E, Wikstrom B, Jensen PB, Krzesinski JM, Rasmussen M, Vanholder R, Rensma PL: Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the Calcification Outcome in Renal Disease (CORD) study. Clin J Am Soc Nephrol 2011, 6:153-159.
• [35]Farrow EG, White KE: Recent advances in renal phosphate handling. Nat Rev Nephrol 2010, 6:207-217.
• [36]Rufino M, De Bonis E, Martin M, Rebollo S, Martin B, Miquel R, Cobo M, Hernandez D, Torres A, Lorenzo V: Is it possible to control hyperphosphataemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 1998, 13:65-67.
• [37]Bachmann S, Schlichting U, Geist B, Mutig K, Petsch T, Bacic D, Wagner CA, Kaissling B, Biber J, Murer H, et al.: Kidney-specific inactivation of the megalin gene impairs trafficking of renal inorganic sodium phosphate cotransporter (NaPi-IIa). J Am Soc Nephrol 2004, 15:892-900.
• [38]Akimoto T, Yoshizawa H, Watanabe Y, Numata A, Yamazaki T, Takeshima E, Iwazu K, Komada T, Otani N, Morishita Y, et al.: Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrol 2012, 13:155. BioMed Central Full Text